Brokerages expect Vericel Corporation (NASDAQ:VCEL) to post earnings per share of ($0.21) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Vericel Corporation’s earnings. Vericel Corporation posted earnings per share of ($0.38) during the same quarter last year, which suggests a positive year-over-year growth rate of 44.7%. The company is expected to announce its next earnings results on Monday, November 6th.
According to Zacks, analysts expect that Vericel Corporation will report full-year earnings of ($0.84) per share for the current fiscal year, with EPS estimates ranging from ($0.93) to ($0.75). For the next year, analysts anticipate that the firm will post earnings of ($0.52) per share, with EPS estimates ranging from ($0.65) to ($0.40). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Vericel Corporation.
Vericel Corporation (NASDAQ:VCEL) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.16. The company had revenue of $16.95 million for the quarter.
Several research firms have weighed in on VCEL. Piper Jaffray Companies reaffirmed a “buy” rating and set a $7.00 target price on shares of Vericel Corporation in a research note on Thursday. BTIG Research set a $6.00 target price on Vericel Corporation and gave the company a “buy” rating in a research note on Wednesday.
WARNING: This article was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/2802678/2802678.html.
Vericel Corporation (VCEL) opened at 3.35 on Friday. The stock’s 50 day moving average is $3.27 and its 200 day moving average is $2.87. The stock’s market capitalization is $109.77 million. Vericel Corporation has a one year low of $2.00 and a one year high of $4.55.
Institutional investors have recently added to or reduced their stakes in the stock. First Washington CORP acquired a new position in Vericel Corporation during the second quarter valued at $2,230,000. Bank of New York Mellon Corp boosted its stake in shares of Vericel Corporation by 13.8% in the second quarter. Bank of New York Mellon Corp now owns 37,202 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 4,523 shares during the last quarter. Perkins Capital Management Inc. boosted its stake in shares of Vericel Corporation by 12.6% in the second quarter. Perkins Capital Management Inc. now owns 257,600 shares of the biotechnology company’s stock valued at $850,000 after buying an additional 28,850 shares during the last quarter. Stonepine Capital Management LLC boosted its stake in shares of Vericel Corporation by 73.3% in the first quarter. Stonepine Capital Management LLC now owns 3,265,323 shares of the biotechnology company’s stock valued at $9,143,000 after buying an additional 1,381,523 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Vericel Corporation by 0.5% in the fourth quarter. Renaissance Technologies LLC now owns 436,900 shares of the biotechnology company’s stock valued at $1,311,000 after buying an additional 2,200 shares during the last quarter. 31.99% of the stock is currently owned by institutional investors.
Vericel Corporation Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.